Astrantus’s Gilead Sciences GILD Stock Holding History

Astrantus’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,100	Closed	-$225K	–	223
2021 Q4	$225K	Buy	+3,100	New	+$214K	0.17%	192

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Astrantus's GILD Position: Q1 2022 in Review

Astrantus sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 3,100 shares — an estimated $225K sold.

Astrantus first reported a position in GILD in Q4 2021 and held it in 1 quarter. The position peaked at $225K in Q4 2021. 1,599 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Astrantus reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
Astrantus sold 3,100 Gilead Sciences shares in Q1 2022, an estimated $225K.
Astrantus first reported a position in Gilead Sciences in Q4 2021 and held it in 1 quarter.
Astrantus's Gilead Sciences position peaked at $225K in Q4 2021.
1,599 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.